MODELLING THE U.S. POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL

HeFH secondary prevention, acute coronary syndrome (ACS) within 12 months of index, ischemic stroke, myocardial infarction > 12 months, other coronary heart disease, peripheral artery disease and HeFH primary prevention.

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2017-03, Vol.69 (11), p.66-66
Main Authors: Sanchez, Robert, Nasir, Khurram, Klimchak, Alexa, Kuznik, Andreas, Joulain, Florence, Briggs, Andrew
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Cardiology
Cardiovascular
Cardiovascular disease
Cholesterol
Internal Medicine
Low density lipoprotein
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HeFH secondary prevention, acute coronary syndrome (ACS) within 12 months of index, ischemic stroke, myocardial infarction > 12 months, other coronary heart disease, peripheral artery disease and HeFH primary prevention.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(17)33455-1